Reunion Neuroscience (TSX:REUN) Total Tax Payable : C$0.00 Mil (As of Mar. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Total Tax Payable?

Reunion Neuroscience's Total Tax Payable for the quarter that ended in Mar. 2023 was C$0.00 Mil.

Reunion Neuroscience Total Tax Payable Historical Data

The historical data trend for Reunion Neuroscience's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Total Tax Payable Chart

Reunion Neuroscience Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Total Tax Payable

Reunion Neuroscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Tax Payable	Get a 7-Day Free Trial										-	-	-	-	-

Reunion Neuroscience Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Reunion Neuroscience Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Reunion Neuroscience (TSX:REUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3

Website

https://www.reunionneuro.com

Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.